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Candida-associated denture stomatitis is the most common form of oral candidal infection, with Candida 
albicans being the principal etiological agent. Candida adheres directly or via an intermediary layer of 
plaque-forming bacteria to denture acrylic. Despite antifungal therapy to treat denture stomatitis, infection 
is reestablished soon after the treatment ceases. In addition, many predisposing factors have been identified 
as important in the development of oral candidiasis, including malnourishment, common endocrine 
disorders, such as diabetis mellitus, antibacterial drug therapy, corticosteroids, radiotherapy and other 
immunocompromised conditions, such as acquired immunodeficiency syndrome (AIDS). These often 
results in increased tolerance to the most commonly used antifungals. So this review suggests new 
therapies to oral candidiasis. 
 




Candida species are commensal yeast in healthy humans 
and may cause systemic infections under immunocompromised 
situations due to its high adaptability to different host niches by 
the activation of appropriate sets of genes in response to 
complex environmental signals (1).  
 Denture stomatitis, also known as atrophic candidiasis, is 
the most common fungal infection in elder patients and in those 
who wear dentures. It is the result of a poor denture 
cleanliness, poor oral hygiene and wearing denture at night, 
which causes a decrease in the salivary flow below denture 
surface, thus facilitating the accumulation of characteristic 
biofilms (48). 
Terai and Shimahara (51) have isolated species of 
Candida in the oral cavity and they found that the frequency 
does not necessarily imply disease in many healthy people 
without clinical manifestation, it just reflects that they may be 
carriers of Candida, with no infections. 
Many predisposing factors have been identified as 
important in the development of oral candidiasis, including 
malnourishment, common endocrine disorders, such as 
diabetes mellitus, antibacterial drug therapy, corticosteroids, 
radiotherapy and other immunocompromised conditions, such 
as acquired immunodeficiency syndrome (AIDS) (49). 
Candida albicans is the most common species of yeasts 
isolated from patients with these predisposing factors (19) and 
non-albicans species have been isolated from the oral cavity of
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immunocompromised patients, such as C. glabrata, C. krusei, 
C. parapsilosis, C. tropicalis, C. guilliermondii e C. 
dubliniensis (40). 
Moreover, Candida may cause systemic infections 
associated with high mortality rates especially in 
immunocompromised patients that are particularly difficult to 
be cured of this kind of infection. This often happens because 
of the increased tolerance to the most commonly used azole 
antifungal drugs, including fluconazole and ketoconazole, 
generally observed in azole-resistant C. albicans infections (17, 
47, 58). So, several studies of new therapies with medicinal 
plants has been made to test the activity of their extracts, 
essential oils and active fractions against these 
microorganisms. 
 
Forms of Oral Candidiasis and Conventional Therapies  
Candida-associated denture stomatitis is the most common 
form of oral candidal infection (56), with Candida albicans 
being the main etiological agent (34). At least 65% of elderly 
denture-wearers carry Candida, and these yeasts have been 
isolated from 93% of patients with denture stomatitis. Candida 
adheres directly or via an intermediary layer of plaque-forming 
bacteria to denture acrylic (polymethylmethacrylate) (15). 
Despite antifungal therapy to treat denture stomatitis, infection 
is reestablished soon after the treatment ceases, suggesting that 
denture plaque may serve as a protected reservoir for C. 
albicans. Although multiple factors are likely to contribute to 
the development of denture stomatitis, it unequivocally 
involves denture plaque (12). 
Since the 1980s, the imidazoles became increasingly more 
popular and seem to have replaced, to a large extent, the 
polyenes for the treatment of oral thrush. Miconazole and 
ketoconazole were found to be effective in in vitro denture 
liners, but they are more expensive and the toxicity of 
ketoconazole is a problem (44). Rapid relapse (7, 11), 
resistance and cross resistance between the azoles have also 
been reported, particularly in association with 
immunosuppressed individuals (16).  
Reasons for the use of nystatin over other drugs in the 
treatment of fungal denture stomatitis still remain: Johnson et 
al. (23) in a clinical study showed nystatin (pastille) to be 
effective in reducing or eliminating the Candida organism 
associated with denture stomatitis; Truhlar et al. (53) showed 
that antifungal activity of nystatin in liners decreased with 
time, and that in vitro fungicidal activity was proportional to 
the concentration of nystatin administrated. The aim of 
antimycotic treatment is to reduce the acute candidal 
overgrowth to levels that can be controlled by the host’s 
defences. Bergendal and Isacsson (6) reported that nystatin 
does not cure denture stomatitis and recolonization of the yeast 
occurs after cessation of drug therapy.  
Braga et al. (10) found that fluconazole in subinhibitory 
concentration was inactive to interfere in the adhesion ability 
of C. glabrata, and in studies of Lyon and Resende (27) a 
reduction in the adherence ability of C. glabrata, C. tropicalis 
and C. parapsilosis to buccal epithelial cells after exposure to 
fluconazole occurred, both among the isolates obtained from 
the denture-wearers with signs of oral candidiasis and normal 
palatal mucosa, considering that C. glabrata frequently shows 
high minimum inhibitory concentrations (MIC) to fluconazole, 
demonstrating the impact of this drug in the adherence ability 
of Candida yeast. 
Antimicrobial resistance is a common phenomenon in 
cells recovered from biofilms (43). Chandra et al. (12) 
demonstrated increased resistance of C. albicans biofilms 
grown on denture acrylic to fluconazole, amphotericin B, 
nystatin and chlorhexidine. Furthermore, C. albicans cells 
resuspended from a biofilm typically maintain some degree of 
resistance to antimicrobials compared to planktonic cells (5). 
Candida albicans cells resuspended from a mature biofilm 
maintained fluconazole resistance even after the biofilm had 
been disrupted (45). Treatment methods directed towards 
reducing initial fungal attachment and subsequent biofilm 
development on denture acrylic would be beneficial in 
reducing the incidence and severity of this condition (43). 
Exposure of Candida to chlorhexidine results in loss of 
structural integrity, less ability to adhere, and fragmentation of 
the cell wall (28). A notable feature of chlorhexidine is that it 
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adheres to salivary glycoproteins in plaque and is slowly 
released over time. Following a 1 min rinse with chlorhexidine, 
30% was retained in the oral cavity for 24h (8). This 
pharmacologic feature of chlorhexidine permits extended 
activity following exposure in the oral environment and allows 
a wide spacing of doses (43). 
 
Resistance in Immunocompromised Patients 
Powderly et al. (42) observed that Candida isolated from 
AIDS patients showed higher MIC values compared to those 
obtained from other patients, including the occurrence of 
isolates resistant to amphotericin B. Macura (29) observed 
resistance to nystatin in 2% of Candida spp. isolates from 
hospitalized patients. Costa et al. (13) evaluated the antifungal 
susceptibility profile of oral isolates obtained from HIV 
patients in a Brazilian hospital and found 8.1% of resistance to 
fluconazole and itraconazole and all isolates are susceptible to 
amphotericin B.  
According to Alves et al. (3), the presence of yeast 
resistant to polyenes is frequent in neutropenic patients, 
especially C. tropicalis and C. lusitaniae. The resistance of C. 
tropicalis to polyenes was also reported by Resende and 
Resende (46), considering samples obtained from hospitalized 
patients. In studies of Pinto et al. (41), C. albicans resistant to 
amphotericin B was isolated from HIV patients, urine samples 
and from a diabetes mellitus patient. A significant number 
(30%) of resistant C. parapsilosis isolated from HIV patients, 
newborns, and from nail was observed.  
For Nakamura and Takahashi (32), C. parapsilosis was the 
major fungi isolated from hospitalized patients in Japan, 
followed by C. albicans and all of those isolates were 
susceptible to fluconazole. Fluconazole has been frequently 
used due to its lower toxicity compared to amphotericin B. 
Viscoli (54) stated that fluconazole is effective and less toxic 
than amphotericin B. According to these authors, resistance to 
fluconazole is not very common in short treatments, however 
in immunocompromised patients under long-term therapy, the 
substitution of susceptible species by naturally resistant ones is 
observed. The increasing incidence of fungal infections and 
widespread use of the newer oral triazoles have led to a 
resurgence of interest in antifungal resistance for these agents.  
 
Mechanism of Action of the Antifungal Drugs  
Polyenes, ergosterol biosynthesis inhibitors and 5-
flucytosin (5-FC) are three common classes of antifungal 
agent. The first two classes of drug act against ergosterol 
directly in some way. Ergosterol is the major sterol of the 
fungal plasma membrane that regulates the fluidity and 
asymmetry of the membrane, and it is important for the proper 
functioning of many membrane-bound enzymes (24). Polyenes, 
including amphotericin B and nystatin, target membranes 
which contain ergosterol. From the 1950s, amphotericin B has 
been the “best drug” used in therapy for severe systemic 
mycoses. 
Ergosterol biosynthesis inhibitors include three groups of 
antifungal agent: allylamines, such as naftifine and terbinafine; 
thiocarbamates, such as tolnaftate and tolciclate; and azole-
based, such as imidazoles (including ketoconazole and 
miconazole) and triazole (including fluconazole, itraconazole, 
and voriconazole). These drugs interact with enzymes involved 
in the synthesis of ergosterol from squalene. Both allylamines 
and thiocarbamates inhibit early steps of ergosterol 
byosinthesis. The major target of azole-based drugs is 
cytochrome P-450 enzyme (lanosterol 14-- demethylase) (24), 
encoded by the ERG11 gene (25). 
Flucytosine (5-fluorocytosine) works as an antifungal 
agent through conversion to 5-fluorouracil within target cells. 
Fluorouracil becomes incorporated into RNA, causing 
premature chain termination, and inhibits DNA synthesis 
through effects on thymidylate synthase. The useful spectrum 
of flucytosine is restricted to pathogenic yeasts (Candida 
species and Cryptococcus neoformans) and is used as 
adjunctive, rather than as primary therapy in the clinic because 
of primary and secondary resistance (36). 
There are six new antifungal agents that are currently 
generating excitement as they pass through the final 
developmental stages of clinical trials. Three of them 
(posaconazole, ravuconazole and voriconazole) are triazole 
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compounds, a subset of the azoles, which are the most 
successful antifungal class in the clinic since the late 1960s. 
The other three (anidulafungin, caspofungin and micafungin) 
are echinocandins and are successors to cilofungin, which was 
abandoned in the 1980s. The echinocandins inhibit synthesis of 
fungal -1,3 glucan, and this represents the first novel target in 
20 years of antifungal drug discovery in terms of clinically 
useful drugs (36).  
Any novel antifungal agent needs to have as broad a 
spectrum of susceptible fungal species as possible, whatever its 
mechanism of action. Genomics-based target searches must 
therefore emphasize genes that are widely represented in the 
fungal kingdom, but are absent or of a demonstrably different 
structure in mammalian cells. If a target is shared between host 
and pathogen, additional constraints are placed on the 
selectivity and toxicity of potential antifungal agents. This 
reduces the apparently large number of potentially useful 
targets that is found from genomics searches based only on C. 
albicans and S. cerevisiae (36). 
 
Development of Resistance 
The chronic use of azole compounds in the prevention of 
systemic mycosis, especially in patients with HIV infection, 
allows the selection of resistant isolated to this therapy (35). 
The widespread use of antibiotics is attributed to promote the 
superinfection of the yeasts from periodontal pockets as a 
result of the disturb caused in commensal microflora 
homeostase (20) and many currently available antifungal drugs 
have several problems including side effects, being ineffective 
against some fungi. An increase number of reports of clinical 
resistance to antifungal agents highlight the need for 
understanding the molecular mechanisms responsible for the 
development of drug resistance (62).  
The molecular mechanisms that result in azole resistance 
include overexpression of (i) the major facilitator efflux pump 
gene MDR1, (ii) the ABC transporter efflux pump CDR gene 
family, and (iii) the azole target enzyme gene ERG11. Point 
mutations in ERG11 are also important for resistance. This 
molecular mechanism of resistance may occur simultaneously 
or independently of each other and exists in different 
combinations (60). In clinical isolates from HIV-positive 
patients, there is a correlation between azole drug resistance 
and overexpression of the MDR1 gene (59). 
Orozco et al (37) determined the mechanism for the 
primary resistance of C. krusei to fluconazole: C. krusei has the 
capacity to efflux fluconazole out of cells better than C. 
albicans. A higher concentration of fluconazole is needed to 
inhibit the synthesis of ergosterol to the same extent in cell 
extracts from C. krusei than in those from C. albicans. This 
result suggested that in addition to efflux, the affinity of 
fluconazole to the target enzymes of these two species is also 
different. 
 
New Antimicrobial Therapies 
Due to the increasing resistance of microorganisms to 
antibiotics administrated, which no longer fully meet the 
medical necessity with respect to spectrum, potency, safety and 
pharmacokinetic properties, increasing the incidence of 
systemic fungal infections, with consequent increase in 
mortality, it is necessary to search for new compounds to act 
against these microorganisms, but in a selective and low 
toxicity way. Thus, several studies of medicinal plants have 
been made to test the activity of their extracts, essential oils 
and fractions act against these microorganisms.  
The problem of the microbial resistance is increasing and 
the future perspective of production and use of antimicrobial 
drugs continue uncertain. Thus, the use of products from 
vegetal origin with potential antimicrobial activity can acquire 
meaning in therapeutical treatments (26, 39). The medicinal 
plants are frequently used in the treatment of some illnesses 
and, recently, have been intensely studied as alternative agents 
for the prevention of diseases, as oral diseases (38). Natural 
products fields produced, approximately, 50% new chemical 
molecules in the years of 2000 - 2006, as well as have 
demonstrated its importance in the development of drugs for 
the treatment of diseases (33).    
Medicinal plants are, however, a rich source of novel, 
complex, and diverse chemical structures, which warrants their 
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more thorough investigation as a potential source of novel 
antifungal agents. The identification of the medicinal plant 
extracts active against Candida isolates of reduced azole 
susceptibility and showing pathogen selectivity is important 
from a practical point of view (50).  
The antifungal compounds of plants are not well known; 
however, the presence of flavonoids and terpenes and a certain 
degree of lipophilicity might determine toxicity by the 
interactions with the membrane constituents and their 
arrangement (52). 
Many extracts of plants and isolated essential oils have 
demonstrated to exert biological activity in vivo and in vitro 
(31). Natural products have been recently investigated more 
thoroughly as promising agents for the prevention of oral 
diseases, especially plaque-related diseases such as dental 
caries (18, 38). 
Here, we demonstrated some studies in which vegetable 
extracts presented activity.  Mardegan (30) analyzed the 
antifungal activity of some vegetable extracts against strains of 
Candida albicans isolated from healthy children and adults 
with periodontal disease, and observed inhibition of these 
clinical samples and on their proteolitic enzymes through 
extracts of Mentha piperita, Tabebuia avellanedae, Casearia 
sylvestris, Arctium lappa, Arrabidae chica e Rosmarinus 
officinalis.  
Anibal (4) observed activity against strains of C. albicans 
CBS-562, C. dubliniensis CBS-7987, C. parapsilosis CBS-604, 
C. tropicalis CBS-94, C. guilliermondii CBS-566, C. utilis 
CBS-5609, C. krusei CBS-573, C. lusitaniae B-06, C. glabrata 
B-07 and C. rugosa B-12 with the extracts of Mentha piperita, 
Arrabidaea chica, Rosmarinus officinalis, Tabebuia 
avellanedae, Syzygium cumini and Punica granatum. Some of 
these plants, such as A. chica, R. officinalis, S. cumini, and P. 
granatum, present among several other compouds, tannins that 
have remarkable antimicrobial activity (22)  
The yeast C. albicans, frequently associated with 
infections in HIV (+) patients, was the most sensitive among 
all tested microorganisms. Lippia sidoides essential oil showed 
an appreciable amount of monoterpenes, a therapeutical 
potential that should not be ignored, and its phenolic 
compounds (thymol and carvacrol) showed activity against oral 
pathogens (9). 
Duarte et al. (13) observed that the oil of Achillea 
millefolium, Mikania  glomerata and Stachys byzantina  have a 
strong activity against C. albicans, while Aloysia triphylla, 
Anthemis nobilis, Cymbopogon martini, Cyperus articulates, 
Cyperus rotundus, Lippia alba, Mentha arvensis and Mentha 
piperita showed moderate activity. 
In a work of Hirasawa and Takada (21), using a catechin (-
)-epigallocatechin gallate combined with amphotericin B, it 
was observed the inhibited growth of C. albicans, and that the 
action was fungicidal. Amphotericin B below the Minimal 
Fungicidal Concentration also stimulates fungal membrane 
permeability. The combined use of amphotericin B and 
catechin may stimulate catechin uptake into the cell by the 
action of amphotericin B, and intracellular catechin may act as 
a fungicidal agent.  
Zhang et al. (63) observed that the fractions TTS-12 and 
TTS-15 of Tribulus terrestris L. had significant antifungal 
activities against the five yeasts tested: C. albicans, C. 
glabrata, C. parapsilosis, C. tropicalis, Cryptococcus 
neoformans. The experiment showed that TTS-12 and TTS-15 
had potent anti-Candida albicans activity, where MIC80 was 
1.0 and 2.3g/mL, respectively.  The steroidal glycosides 
tested in the experiment are from the same chemical class, but 
only TTS-12 and TTS-15 exhibited significant antifungal 
activity against that cited yeasts. These results indicate that 
there are critical structural features that are responsible for the 
antifungal activity.  
As plants produce many compounds with antimicrobial 
properties, it is expected that some programs of valuation to 
antifungal activity may indicate these compounds to the 
development of these new antimicrobial drugs (2). A 
successful therapy can be defined as “a suitable agent 
prescribed to treat the right organism at appropriate dosage”. 
Epidemiological studies by surveillance to determine the true 
frequency of antifungal resistance may be the first step to 
control the emergence of antifungal resistance. Rapid 
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identification of fungal pathogens and the measurement of the 
MIC of clinical isolates in vitro may be helpful. Knowledge 
gained from studying the mechanisms of antifungal resistance 
may provide ideas on how to limit the emergence of resistance 
to those marketed antifungal agents and to develop safer and 
better compounds for the next generation of antifungal agents 
(62). New treatment strategies, especially those active against 




We presented in this review the necessity to develop new 
therapy agents against opportunistic fungi of the Candida 
genera which, as other microorganisms, have the ability to 
acquire resistance to antimicrobians during prolonged 
treatment, especially in immunocompromised patients. One of 
the most promissory sources to the research of new agents is 
found in plants, which have compounds with antimicrobians 
properties that is being studied by diverse researchers, but 
many of these compounds are not known yet. The investigation 
of these active principles, once they have different targets that 
were found in the antifungal in use, is a potential area that must 
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